Stelara (ustekinumab) prior authorization denied appeal
IL-12/23 inhibitor
Typical PA criteria
- Diagnosis (psoriasis, psoriatic arthritis, Crohn's, UC)
- Trial of TNF inhibitor
- Negative TB screen
Why your PA was denied
- Step therapy with TNF inhibitor not completed
- Biosimilar preferred
- Indication not covered
Evidence that overturns the denial
- ✓Documented TNF inhibitor failure or intolerance
- ✓Disease activity scores
- ✓Negative TB screen
Biosimilars launching; expect step-therapy denials to require biosimilar trial.
Free analysis identifies the cited policy and missing evidence. Then a finished letter that maps your chart to the criteria.
FAQ
Why was my Stelara (ustekinumab) prior authorization denied?+
The most common reasons are: Step therapy with TNF inhibitor not completed; Biosimilar preferred; Indication not covered. Your denial letter names the specific criteria you did not meet.
How do I appeal a Stelara (ustekinumab) denial?+
File a written appeal within 180 days that cites the insurer's clinical policy, includes a letter of medical necessity from the prescriber, and documents the criteria the insurer requires.
What evidence overturns a Stelara (ustekinumab) denial?+
Documented TNF inhibitor failure or intolerance; Disease activity scores; Negative TB screen.
What if the plan excludes Stelara (ustekinumab) entirely?+
Plan exclusions are different from medical-necessity denials. Check the Summary Plan Description. If the drug is fully excluded, an appeal will not overturn it; you may need a formulary exception or manufacturer assistance program.
Other drugs
- Wegovy (semaglutide)
- Zepbound (tirzepatide)
- Ozempic (semaglutide)
- Mounjaro (tirzepatide)
- Saxenda (liraglutide)